Shreya Mukherjee is a Partner in the Corporate and Commercial, Mergers and Acquisitions and Private Equity practice group in the Mumbai office. She is dual-qualified and admitted to practice in India and in New York (United States).
Shreya has advised clients across the board – promoters/founders, private equity investors, sovereign wealth funds, corporate strategic investors (both domestic and foreign) – in a wide range of general corporate and M&A mandates across sectors, including complex structuring, strategic investments and exits, private equity investments, business transfers / asset transfers and corporate restructurings.
Shreya’s special focus is on mandates in the financial services space (including, mutual funds (MF), banks, NBFCs, insurance) and she has extensive experience in this area – both on transactional and regulatory aspects. She also collaborates with financial sector regulators to support policy development. Recently, Shreya played an active role in advocating for the private equity and venture capital (PE and VC) community (through the Indian Venture Capital Association (IVCA)) by engaging with the IRDAI (Indian insurance regulator) and made several submissions and presentations to the IRDAI in this regard. This resulted in the overhaul of the insurance sector investment framework via the introduction of IRDAI (Registration of Indian Insurance Companies) Regulations, 2022. She has also made similar submissions to SEBI (Indian securities regulator) which culminated into investor-friendly amendments being introduced in the MF investment regime in 2023 (including PE funds being permitted to become ‘sponsors’ of an MF).
Corporate and Commercial
Mergers and Acquisitions
Private Equity
Niva Bupa Health Insurance and True North in Niva Bupa’s fund raise of up to INR 800 crores (approx.) from multiple financial investors such as Temasek, Motilal Oswal, Paragon and SBI Life Insurance.
True North on the regulatory aspects in relation to its secondary stake-sale (partial exit) to Bupa for INR 2700 crores (approx.), to transfer control of Niva Bupa Health Insurance to Bupa.
Unichem Laboratories Limited and Dr. Prakash A. Mody (promoter of Unichem) in relation to proposed acquisition of 33.38% of the paid-up equity share capital of Unichem Limited by IPCA Laboratories Limited from Dr. Prakash A. Mody for a total consideration of INR 1034.06 crores and up to INR 805.44 crores towards open offer.
Kedaara Capital, on its primary investment of INR 800 crores in Avanse Financial Services Limited, a new-age education focused technologically advanced non-banking financial company
Siemens Aktiengesellschaft and the Siemens group on the sale of 71.70% equity shares of Siemens Limited (SIL), an Indian listed company, by Siemens Aktiengesellschaft to its subsidiaries, as follows: sale of 24% (out of 71.70%) to Siemens Gas and Power Holding B.V. (Siemens GP) and sale of remaining 47.70% (out of 71.70%) to Siemens International Holding B.V; through strategically structured block deals on the floor of BSE Limited. The total consideration for transaction was over INR 26,757 crores (~ USD 3.57 billion).
A prominent private equity player on its proposed acquisition of IDFC Mutual Fund, as part of a consortium.
